Anticoagulant therapy at difficult-to-treat patients with atrial fibrillation

• Pavlova Tatyana V.
• Mullova I.S.
• Duplyakov Dmitriy V.

AbstractThe risk of stroke and systemic embolism in patients with atrial fibrillation increases with age and in patients with impaired renal function. Apixaban, a novel oral anticoagulant, was compared with warfarin in the ARISTOTLE trail and showed reduction of the rate of stroke, death and bleeding regardless of age and renal function.

Keywords:atrial fibrillation, stroke prevention, apixaban

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)